Palbociclib induces the apoptosis of lung squamous cell carcinoma cells via Rb-independent STAT3 phosphorylation

Wenjing Xiang  
Guangdong Pharmaceutical University

Wanchen Qi  
First Affiliated Hospital of Guangzhou Medical University

Huayu Li  
Guangdong Pharmaceutical University

Jia Sun  
Guangdong Pharmaceutical University

Chao Dong  
Guangdong Pharmaceutical University

Haojie Ou  
Guangdong Pharmaceutical University

Bing Liu  
Guangdong Pharmaceutical University  https://orcid.org/0000-0002-3144-5673

---

Research Article

**Keywords:** lung squamous cell carcinoma, CDK4/6 inhibitor, palbociclib, STAT3, Rb, Myc

**Posted Date:** June 14th, 2022

**DOI:** https://doi.org/10.21203/rs.3.rs-1733404/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Lung squamous cell carcinoma (LUSC) treatment response is poor and treatment alternatives are limited. Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, has recently been approved for hormone receptor-positive breast cancer patients and applied in multiple preclinical models, but its use for LUSC therapy remains elusive. Here, we investigated whether palbociclib induced cell apoptosis and dissected the underlying mechanism in LUSC. We found that palbociclib induced LUSC cell apoptosis through inhibition of Src tyrosine kinase/signal transducers and activators of transcription 3 (STAT3). Interestingly, palbociclib reduced STAT3 signaling in LUSC cells interfered by retinoblastoma tumor suppressor gene (RB), suggesting that pro-apoptosis effect of palbociclib was independent of classic CDK4/6-RB signaling. Furthermore, palbociclib could suppress IL-1β and IL-6 expression, and therefore blocked Src/STAT3 signaling, which were rescued by either recombinant human IL-1β or IL-6. Moreover, Myc mediated the sensitivity of LUSC cells to palbociclib. Our findings that palbociclib induces apoptosis of LUSC cells through the Src/STAT3 axis in RB-independent manner, and provide options for clinical LUSC patients.

1. Introduction

Lung cancer remains the leading cause of mortality among various malignant tumors. Lung squamous cell carcinoma (LUSC) is a common subtype of non-small cell lung cancer (NSCLC) affecting over 300,000 individuals worldwide annually, and has poor therapeutic response and prognosis [1]. Unlike lung adenocarcinoma, LUSC is a deadly disease, which no effective therapies have been approved [2]. Therefore, there is an urgent need to develop novel targeted therapeutic drugs for LUSC patients.

Cyclin-dependent kinase 4 (CDK4) and the closely related CDK6 are important to cell cycle entry as promoting the progression of cells into the DNA synthesis phase of the cell cycle [3]. CDK4/6 interacts with the D-type cyclins (cyclin D), forming functional complexes that phosphorylate the retinoblastoma (Rb) tumor suppressor gene product [4]. Conversely, p16INK4A (p16) encoded by CDKN2A gene, blocks the functioning of the CDK4/6 complexes with cyclin D by directly binding to CDK4 and CDK6, thereby preventing phosphorylation of Rb [5]. Rb is an active transcriptional repressor when bound to transcription factors such as members of the E2F family. Inactivation of Rb by phosphorylation causes the release of E2F, allowing transcription of genes important for DNA synthesis [6]. Progression of normal human cells into malignant proliferation involves the genetic alteration of this signaling, such as inactivation of either p16 or Rb, or amplification of cyclin D1 or CDK4/6. Especially for LUSC, a comprehensive study of 178 LUSC specimens revealed that significant alteration in CDKN2A and Rb1 gene was identified in 72% of LUSC cases, and CDK4/6 gene was frequently amplified in CDKN2A intact tumor [7, 8]. Thus, cyclin D-CDK4/6 axis may be an attractive target in the treatment of LUSC.

Three CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) are currently approved in clinical practice. They bind to the CDK4/6 ATP pocket, leading to a substantial inactivation of cyclin D-CDK4/6 complexes. As CDK4/6 inhibitors had potent efficacy and tolerable adverse effects, they were used to
treat various neoplasms [9]. Palbociclib, the first CDK4/6 inhibitor, was approved by the US Food and Drug Administration (FDA) as a therapeutic for estrogen receptor (ER) positive metastatic breast cancer [10], and also exhibits pre-clinical efficacy in multiple cancers including NSCLC. However, the mechanism of palbociclib in LUSC remain unclear, which may limit its wider clinical use.

This study was designed to explore the action of palbociclib and the underlying mechanisms in LUSC. Here, we reported that palbociclib conferred apoptosis on LUSC cells via inhibition of Src/signal transducers and activators of transcription (STAT) 3 signaling. These findings suggest that palbociclib is an alternative drug for LUSC treatment, and provides a novel mechanism beyond canonical targets. Our studies can provide a powerful reference for the individualized treatment of LUSC patients.

2. Materials And Methods

2.1 Materials

Palbocicilib (S1116), stattic (S7024) and dasatinib (S1021) were purchased from Selleck Chemicals (SH, China). Recombinant human IL-6 (rhIL-6, Cat. No 206-IL) and IL-1β (rhIL-1β, Cat. No 269-1R) were purchased from R&D Systems (Minneapolis, USA).

2.2 Cell Lines and Culture

The human LUSC H520 and H226 cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (SH, China). All cells were cultured in RPMI-1640 (GIBCO, Invitrogen, USA), supplemented with 10% FBS (GIBCO, Invitrogen, USA) at 37°C in a humidified 5% CO2 atmosphere (Thermo Fisher Scientific, Waltham, MA, USA).

2.3 Cell Viability Assay

Cells were seeded in 96-well plates at 5,000 cells per well in 100 µL of culture medium. Following adhesion of cells to the well, about 100 µL of fresh media and 20 µL of dimethyl thiazolyl diphenyl tetrazolium salt (MTT, Sigma-Aldrich, St. Louis, MO) solution was added to each well. Then, the cells were cultured for 4 h at 37°C in a humidified 5% CO2 atmosphere. Removed the supernatants, formazan crystals were dissolved in 150 µL of DMSO. The plates were incubated for 10 min with gentle shaking before measuring the absorbance at 570 nm using a microplate reader (Thermo Fisher Scientific Multiskan™ FC, USA). IC50 values were calculated using GraphPad Prism v. 7.01 (GraphPad Software, CA, USA).

2.4 Flow cytometry analysis

Cells were harvested and apoptosis was detected by a FITC Annexin V Apoptosis Detection Kit (BB-4101-3, BestBio NJ, China). According to the manufacturer’s protocols, cells were suspended in 400 µL 1x binding buffer with 5 µL Annexin V-FITC and 10 µL propidium iodide (PI) followed by incubation for 15 min at 4°C in the dark. Finally, apoptosis was analyzed by flow cytometry (Thermo Fisher Scientific, Attune NxT, USA).
2.5 Western Blotting

Cell were collected and lysed after treatment, membranes were incubated with primary antibodies as follows: anti-p-STAT3, p-Src, phospho-JAK2, p-Rb, p-Smad1/5/9, STAT3, Src, JAK2, Rb, Smad1/5/9, Survivin, Myc, IL-1β, IL-6 and β-tubulin were purchased from Cell Signaling Technology (Beverly, MA, USA). Membranes were probed with horseradish peroxidase (HRP)-labeled anti-rabbit secondary antibody from Cell Signaling Technology. The signal was recorded using the enhanced chemoluminescence reagent (ECL plus; Thermo Fisher Scientific) before exposing film.

2.6 Real-Time PCR

Total RNA was extracte with Trizol reagent (Invitrogen) from cells and reverse transcribed to cDNA using a ReverTra Ace reverse transcriptase (TOYBO, FSQ-301, Japan) according to the manufacturer's protocol. Real-time RT-PCR was performed with the SYBR Green Realtime PCR Master Mix (TOYBO, Japan, QPK-201) on an iCycler (Bio-Rad, OSA, Japan) following the manufacturer's instructions. The primer sequences were as follows: IL-1β forward primer: 5'-GCCAGTGAAATGATGGCTTAT-3'; IL-1β reverse primer: 5'-GGTCCTGGAAGGAGCAC-3'; GAPDH forward primer: 5'-GGCACCGTCAAGGCTGAGAAC-3'; GAPDH reverse primer: 5'-CATGCTGGTGAAGACGCAGTC-3'; IL-6 forward primer: 5'-TAGGCCGCCCCACACGAGACAG-3'; IL-6 reverse primer: 5'-GGCTGGCATTTGTGTGTTG-3'; IL-8 forward primer: 5'-CACCAGCTTTCAAGCTGGTGC-3'; IL-8 reverse primer: 5'-TCATGGATCTTGCTCTCAGCTCTC-3'; IL-10 forward primer: 5'-ATGCCCCAAAGCTGAGAACCAAGACCCA-3'; IL-10 reverse primer: 5'-TCTCAAGGGGCTGTGGTCAG-3'; The gene expression levels for each amplification were calculated by using the ΔΔCT method and normalized against GAPDH mRNA.

2.7 ELISA

Levels of IL-6 and IL-1β in the culture supernatant of drug-treated cells were determined by ELISA. Each cytokine was detected according to the manufacturer's protocol using Human Quantikine ELISA Kits (R&D Systems, Minneapolis, MN, USA).

2.8 SiRNA transfection

SiRNAs against Rb, Myc, and a non-target control were from Shanghai GeneChem Co., Ltd. (SH, China). The siRNAs were transfected with Lipofectamine 3000 (Invitrogen, L3000015) overnight according to manufacturer's instruction.

2.9 Myc plasmid transfection

For transfection of Myc overexpressing plasmid, the plasmid (Addgene; Plasmid number: 16011) was transfected into H520 and H226 cells together with Lipofectamine 3000 (Invitrogen, L3000015) overnight according to manufacturer's instructions.

2.10 Statistical Analysis
3. Results

3.1 Palbociclib exhibits a pro-apoptotic activity for LUSC cells

To evaluate the inhibitory effect of palbociclib on LUSC cells, we first determined its influence on cell viability in two LUSC cell lines (H520 and H226) by MTT assay. Palbociclib markedly decreased the viability of H520 and H226 cells in a dose-dependent manner with the half-maximal inhibitory concentration ($IC_{50}$) of 8.88 ± 0.67 µM and 9.61 ± 0.72 µM, respectively (Fig. 1a). Action of apoptosis was confirmed by flow cytometry analysis in palbociclib-treated cells (Figs. 1b-1c). These results indicate that palbociclib can suppress LUSC cell viability.

3.2 Inhibition of STAT3 signaling decreases palbociclib-induced LUSC apoptosis

To investigate the potential mechanism underlying palbociclib-induced apoptosis in LUSC cells, we examined the STAT3 signaling, which was constitutively activated in LUSC progression [11] and closely associated with apoptosis in various cancers [12]. Palbociclib dose-dependently suppressed STAT3 activity in H520 and H226 cells, as reflected by decreased STAT3 phosphorylation (Fig. 2a). Besides, palbociclib significantly inhibited the expression of survivin, a well-known target of STAT3. Next, we sought to clarify whether STAT3 inhibition induced by palbociclib sensitizes LUSC cells to apoptosis. Stattic (10 µM), a selective STAT3 inhibitor, had similar effect on pro-apoptosis as palbociclib, which was determined by flow cytometry. When STAT3 activity was suppressed by stattic, palbociclib (15 µM) could not induce additional pro-apoptotic effect in H520 and H226 cells (Fig. 2b-2d). These results strongly support that palbociclib induces apoptosis via STAT3 inhibition in LUSC cells.

3.3 Palbociclib inhibits STAT3 phosphorylation via Src inhibition in Rb-independent manner

Given the Rb is the critical downstream effector of CDK4/6, we examined whether Rb mediated palbociclib-inhibited STAT3 phosphorylation in LUSC cells. Palbociclib could efficiently suppress Rb phosphorylation in a dose-dependent manner in H520 and H226 cells (Fig. 3a). Then, we constructed Rb-deficient cells using Rb siRNA transfection. The knockdown efficiency of Rb siRNA was shown in Fig. 3b and 3c showed that Rb knockdown had little or no effect on STAT3 phosphorylation. Specifically,
Palbociclib could reduce STAT3 phosphorylation even in Rb-deficient cells. Therefore, the above data indicate that palbociclib inhibits STAT3 activity irrespective of Rb status in LUSC cells.

A previous study showed that CDK4 inhibition directly inactivated Smad1/5/9 and subsequently dephosphorylated STAT3 in human mesenchymal stem cells [13]. However, our study found palbociclib had no influence on Smad1/5/9 phosphorylation in H520 and H226 cells (Fig. 4a). Janus kinase 2 (JAK2) and Src family kinases are the well-known upstream activating kinases of STAT3 [14]. Thus, we next explored whether JAK2 and Src mediated effects of palbociclib on STAT3 inactivation. Figure 4b showed that palbociclib dose-dependently reduced Src phosphorylation, while had no or little effect on JAK2. To further elucidate the role of Src in palbociclib-mediated STAT3 activity, we used dasatinib to inhibit Src activity in H520 and H226 cells. As shown in Fig. 4c, dasatinib (50 nM) produced a similar inhibition of Src phosphorylation compared with palbociclib (15 µM). Furthermore, palbociclib plus dasatinib treatments could not induce additional decrease in Src phosphorylation compared with dasatinib alone (Fig. 4c). Taken together, these findings reveal that palbociclib suppresses STAT3 activity via Rb-independent manner, but through Src inactivation in LUSC cells.

### 3.4 Palbociclib inhibits Src/STAT3 signaling via suppressing IL-1β and IL-6 expression in LUSC cells

Many inflammatory cytokines have been reported to activate Src kinase and STAT3 signaling in cancers [15]. Therefore, we sought to detect four important pro-inflammatory cytokines interleukin (IL)-10, IL-1β and IL-6 as well as IL-8. Palbociclib dose-dependently reduced IL-1β and IL-6 expression at the transcriptional level, whereas exerted no effects on IL-10 and IL-8 in H520 and H226 cells (Fig. 5a). Next, we performed ELISA to investigate the effect of palbociclib on the secretion of IL-1β and IL-6. Palbociclib significantly suppressed IL-1β and IL-6 production in H520 and H226 cells (Fig. 5b). To further explore the potential role of IL-1β and IL-6, we incubated the palbociclib-treated H520 and H226 cells with the recombinant human IL-1β (rhIL-1β) or IL-6 (rhIL-6). These results showed that either rhIL-1β or rhIL-6 could substantially rescue the inhibitory effect of palbociclib (15 µM) on Src and STAT3 phosphorylation (Fig. 5c-5d). These data suggest that palbociclib inhibits Src/STAT3 signaling via decreasing production of IL-1β or IL-6 in LUSC cells.

### 3.5 Myc mediates the sensitivity of LUSC cells to palbociclib

Myc is an oncogene and frequently overexpressed in LUSC [16]. Moreover, survivin is required for the survival of cells overexpressing Myc [17]. Our finding that palbociclib significantly reduced survivin expression implies that palbociclib may be more sensitive in Myc-overexpressed LUSC cells. To confirm this hypothesis, we first constructed Myc-knockdowned H520 and H226 cells via Myc siRNA transfection (Fig. 6a). Figure 6b showed that palbociclib elicited weaker inhibition of cell viability in Myc-knockdowned
cells with the IC$_{50}$ of 14.89 ± 1.44 µM and 16.14 ± 1.41 µM, than in control siRNA-transfected H520 and H226 cells with the IC$_{50}$ of 8.70 ± 0.88 µM and 9.27 ± 0.64 µM, respectively.

Next, we transfected H520 and H226 cells with Myc plasmid to overexpress Myc (Fig. 6c). As expected, the results showed that cells transfected with Myc plasmid with the IC$_{50}$ of 6.88 ± 0.61 µM and 7.76 ± 0.64 µM were more sensitive to palbociclib than transfected with empty vector plasmid with the IC$_{50}$ of 8.81 ± 0.76 µM and 9.74 ± 0.70 µM, respectively (Fig. 6d). Furthermore, cells transfected with Myc plasmid showed significant increments in apoptosis compare with cells transfected with empty plasmid after palbociclib (15 µM) treatment (Fig. 6e). These findings suggest that Myc overexpression enhances the sensitivity of LUSC cells to palbociclib.

4. Discussion

Recently, in the context of lung cancer, palbociclib has been reported to induce an apoptotic response in lung adenocarcinoma cell line [18]. Another study reported that dual CDK4/6 inhibition by palbociclib induced apoptosis and senescence in esophageal squamous cell carcinoma cells [19]. In our study, we found that palbociclib dose-dependently induced apoptosis of LUSC cells. These works suggest that palbociclib has anti-cancer effects by inducing cell apoptosis and not restricting to growth arrest. Given the current inefficiency in therapy of LUSC, palbociclib might be an effective alternative therapeutic strategy for LUSC patients, at least in part, by inducing cell apoptosis.

STAT are highly conserved family of transcription factors that are activated by phosphorylation to regulate gene expression [20]. Among the seven STATs, STAT3 signaling activation contributes to progression of cancers [20], while inhibition of STAT3 signaling leads to apoptosis of various cancer cells including lung cancer [21]. To our knowledge, we for the first time found that palbociclib effectively inhibited the STAT3 activity in LUSC cells, which was further confirmed by decreased expression of its downstream, survivin. Further experiments showed that STAT3 inhibitor did not induce additional increase in apoptosis compared with palbociclib alone. These works suggested that STAT3 inactivation play important role in palbociclib-induced apoptosis in LUSC cells. Previous studies have indicated that Rb is a direct downstream protein of CDK4/6 complex and its action determined anti-cancer activity of palbociclib [22]. Our results indicate that when Rb expression was silenced, palbociclib treatment also exert inhibition of STAT3 phosphorylation in LUSC cells. These data strongly support that palbociclib mediated LUSC cells apoptosis via inhibition of STAT3 phosphorylation but not classic Rb signaling. This finding is in keeping with previous work, which reported that palbociclib consistently suppresses tumor growth under Rb-deficient conditions. These results together suggested that Rb dependence was not general for CDK4/6 inhibitor treatment, and palbociclib exerted its cytotoxic effects at least partly by targeting STAT3 signaling beyond canonical CDK4/6-Rb signaling. Our findings suggested that palbociclib treatments might benefit STAT3-positive patients with LUSC, and provide useful information for ongoing and future clinical studies.
A previous study showed that CDK4 inhibition directly inactivated Smad1/5/9 and subsequently dephosphorylated STAT3 in human mesenchymal stem cells [13]. In this study, palbociclib had no influence on Smad1/5/9 phosphorylation in LUSC cells. This may be cell context dependent, perhaps reliant on the necessity of CDK4 versus CDK6 function for different cell types. STAT3 is mainly activated by phosphorylation of tyrosine, which can be mediated by many tyrosine kinases including the Src and JAK families [23, 24]. Our study found palbociclib could reduce Src phosphorylation while have no effects on JAK2 phosphorylation in H520 and H226 cells. Further study showed that palbociclib could not induce additional decrease in STAT3 phosphorylation in cells treated with Src inhibitor. To sum up, these findings reveal that palbociclib suppresses STAT3 activity via Src/STAT3 axis in Rb-independent manner.

Human lung cancer cell-related inflammatory signaling can promote cell proliferation and survival [25, 26]. Some inflammatory cytokine signature predicted the effectiveness of the anti-cancer medication, for example, IL-6 level is a prognostic marker for survival in advanced NSCLC patients or those treated with chemotherapy [27]. In the current study, palbociclib treatment dose-dependently reduced expression and secretion of IL-1β and IL-6 while has no effects on IL-8 and IL-10, indicating that the decrease of IL-6 or IL-1β, but not IL-8 and IL-10, may be serve as a potential biomarker to predict clinical response to palbociclib for LUSC patients. A previous study indicated that palbociclib improved cardiac dysfunction in diabetic cardiomyopathy by preventing inflammatory cytokine release [28]. These studies suggested that palbociclib resulted in not only cell cycle arrest but also decreased inflammatory response, which hinted that palbociclib might be beneficial not only cancers but also inflammatory-related diseases. Future studies are warranted to test this hypothesis. Most importantly, recombinant human IL-1β or IL-6 could rescue the inhibitory effects on Src and STAT3 activity in palbociclib-treated LUSC cells. These observations strongly demonstrated the palbociclib inhibited Src/STAT3 signaling in LUSC cells probably suppression of IL-1β and IL-6 production, and further indicated that inflammatory signaling is of importance on palbociclib-induced apoptosis in LUSC.

Myc is amplified in up to 33% of NSCLC patients and a prognostic marker of early-stage tumors [29]. Our discovery that Myc mediated sensitivity of LUSC cells to apoptosis in response to palbociclib suggested that CDK inhibitors can selectively target tumor cells with specific genetic alterations. Previous works also identified that a form of synthetic-lethal interaction between Myc overexpression and CDK1 inhibition in engineered breast cancer cell lines [30]. Our research into the effects of CDK4/6 inhibitor on LUSC identified high Myc expression as a potential marker of sensitivity, which indicated that palbociclib have value in the treatment of human LUSC malignancies that over-express Myc.

Our work demonstrated that palbociclib promoted apoptosis in LUSC cell lines, and might be an effective alternative therapeutic strategy for LUSC patients. Specifically, we disclosed for the first time that palbociclib induced cell apoptosis via inhibition of Src/STAT3 signaling but independent on canonical CDK4/6-Rb signaling. Furthermore, blockage of IL-1β or IL-6 mediated palbociclib-inhibited Src/STAT3 signaling. Moreover, Myc can regulate LUSC cells apoptosis in response to palbociclib. Taken together, palbociclib can exert its anti-LUSC activities beyond simply enforcing cytostatic growth arrest, which might be useful in the treatment of human malignant progression of LUSC that over-express STAT3.
Abbreviations

Cyclin D  D-type cyclins
CDK4/6  Cyclin-dependent kinase 4/6
DCF-DA  2,7-Dichlorofluorescein diacetate
DMSO  Dimethyl Sulfoxide
ER  estrogen receptor
ELISA  Enzyme-linked immunosorbent assay
FBS  Fetal bovine serum
IL  interleukin
JAK2  Janus kinase 2
LUSC  Lung squamous cell carcinoma
MTT  3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide, Thiazolyl Blue Tetrazolium Bromide
NSCLC  Non-small cell lung cancer
PBS  Phosphate buffered solution
PI  Propidium iodide
(RPMI)-1640  Roswell park memorial institute
STAT3  Signal transducers and activators of transcription 3
TUNEL  Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling

Declarations

Acknowledgements

The authors thank the National Natural Science Foundation of China (No. 81972821) and the projects of Guangzhou key laboratory of construction and application of new drug screening model systems (No. 201805010006).

Funding

This work was supported by the National Natural Science Foundation of China (No. 81972821) and the projects of Guangzhou key laboratory of construction and application of new drug screening model systems (No. 201805010006).

Competing interests
All authors declare that they have no conflict of interest or competing interests.

Author contributions

Bing Liu designed this study. Bing Liu and Wenjing Xiang drafted the manuscript. Wenjing Xiang, Wanchen Qi, Huayu Li contributed equally to this work. Jia Sun, Haojie Ou and Chao Dong performed the experiments. Wenjing Xiang and Wanchen Qi conducted the statistical analysis. All authors read and approved the final manuscript. All authors read and approved the final manuscript.

Data availability

The data generated during the present study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

References


Figures
Figure 1

Palbociclib inhibits cell viability and induces apoptosis in LUSC. (a) The effect of palbociclib on the viability of H520 and H226 cells, determined by MTT. (b-c) The effect of palbociclib (0 to 20 µM) treatment on apoptosis of H520 and H226 cells. Significantly different from 0 µM group, ****p < 0.0001, n = 3.
Figure 2

Palbociclib induces apoptosis via STAT3 inhibition in LUSC cells. (a) Palbociclib inhibited survivin and phosphorylation of STAT3 in H520 and H226 cells, as revealed by western blotting. (b) After administration of palbociclib with or without stattic, the expression and phosphorylation of STAT3 were analyzed by western blotting. (c-d) After administration of palbociclib with or without stattic, effects of
Palbociclib on cell apoptosis determined by flow cytometry. Significantly different from control or 0 µM group, * \( p < 0.05 \), ** \( p < 0.01 \), **** \( p < 0.0001 \), \( n = 3 \). NS, not significantly, \( p > 0.05 \), \( n = 3 \).

Figure 3

Palbociclib inhibits STAT3 phosphorylation via independence of Rb. (a) Palbociclib (0 to 20 µM) suppressed Rb phosphorylation in H520 and H226 cells. (b) Rb siRNA was used to construct Rb-deficient
H520 and H226 cells. (c) H520 and H226 cells were transiently transfected with the siRNA against Rb, and then treated with palbociclib. Significantly different from control or 0 µM group, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, n = 3. NS, not significantly, $p > 0.05$, n = 3.

Figure 4
Palbociclib inhibits STAT3 phosphorylation via Src kinase. (a) Palbociclib had no influence on the Smad1/5/9 phosphorylation. (b) Palbociclib dose-dependently reduced Src phosphorylation and had no effect on phosphorylation and expression of JAK2 in H520 and H226 cells. (c) After administration of dasatinib or dasatinib plus palbociclib, the phosphorylation of Src was analyzed by western blotting. Significantly different from control or 0 µM group, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, n = 3. NS, not significantly, $p > 0.05$, n = 3.
Figure 5

Palbociclib inhibits Src/STAT3 signaling via IL-1β and IL-6 production. (a) The effect of palbociclib on the mRNA expression of inflammatory cytokine (IL-1β, IL-6, IL-8 and IL-10) in H520 and H226 cells. (b) After administration of palbociclib, the content of IL-1β and IL-6 in H520 and H226 cells were measured using ELISA kit, respectively. (c-d) Western blotting analyzed STAT3 and Src expression in palbociclib-treated H520 and H226 cells with the recombinant human IL-1β (rhIL-1β) or IL-6 (rhIL-6). Significantly different from control or 0 μM group, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, n = 3. NS, not significantly, $p > 0.05$, n = 3.
Figure 6

Myc mediates the sensitivity of LUSC cells to palbociclib. (a) The efficiency of Myc silencing was confirmed by western blotting. (b) Cell viability in control and Myc-interfered H520 and H226 cells stimulated by palbociclib determined by MTT assay. (c) The efficiency of Myc overexpression was analyzed by western blotting in H520 and H226 cells. (d) The effect of palbociclib on the viability of H520 and H226 cells with or without Myc overexpression, determined by MTT assay. (e) Myc overexpression
promotes palbociclib-induced apoptosis in H520 and H226 cells determined by flow cytometry. Significantly different from control or 0 µM group, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, n = 3.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Representativedata.pdf
- Supplementdata1.pdf
- Supplementdata2.pdf